Alzamend Neuro Net Cash Flow 2020-2025 | ALZN

Alzamend Neuro net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Alzamend Neuro Net Cash Flow 2020-2025 | ALZN

Alzamend Neuro net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$229.7B
Amgen (AMGN)$153.5B
Gilead Sciences (GILD)$149.5B
Vertex Pharmaceuticals (VRTX)$96B
Bristol Myers Squibb (BMY)$93.5B
CSL (CSLLY)$83.2B
GSK (GSK)$76.9B
Regeneron Pharmaceuticals (REGN)$57.9B
Alnylam Pharmaceuticals (ALNY)$57B
Argenex SE (ARGX)$39.1B
BioNTech SE (BNTX)$26.3B
Insmed (INSM)$23.9B
Royalty Pharma (RPRX)$20.3B
Biogen (BIIB)$18.8B
Incyte (INCY)$15.5B
Illumina (ILMN)$14.6B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$13.5B
Ascendis Pharma (ASND)$12B
BioMarin Pharmaceutical (BMRN)$10.9B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exelixis (EXEL)$10.1B
Moderna (MRNA)$9.9B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$7.9B
Halozyme Therapeutics (HALO)$7.7B
Exact Sciences (EXAS)$7.7B
Roivant Sciences (ROIV)$7.6B